System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Elisabetta Abruzzese is an expert in Hematology at St. Eugenio Hospital (Italy). As of October 2026, ScienceLeadR ranks Elisabetta Abruzzese in the top 1% of experts worldwide for Leukemia. Elisabetta Abruzzese has authored 475 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 7 of them ongoing. SLR score: 1,361 (community average: 125). How the SLR is computed.

LeadR Profile

Elisabetta Abruzzese St. Eugenio Hospital Italy
1 361 ScienceLeadR Reputation 1361

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1997 - 2026
Source: PubMed

University of Rome Tor Vergata

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 475

Citations

Citations: 9 709 1st author: 37 Last author: 25 Unique author: 5

Main journals

Blood 201
Haematologica 21
Hemasphere 19
Cancer 18
Ann Hematol 16

Best Journals

N Engl J Med 2
J Clin Oncol 1
Nat Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.
PMID 42701040 — quality of life, hematology, leukemia, leukemia, myeloid, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive		Blood Rev20260
Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.
PMID 42534710 — quality of life, leukemia, signs and symptoms, leukemia, myeloid, therapeutics, health surveys, leukemia, myelogenous, chronic, bcr-abl positive		Front Oncol20260
Multidisciplinary Characterization of Rare MPL Y591 and R592 Variants in Myeloid Disorders: From Clinical Correlation and Literature-Based Evidence to In Silico Predictors and Structural Bioinformatics.
PMID 42398799 — thrombopoietin, genes, hematology, neoplasms, research, mutation		Exp Hematol20260
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.
PMID 42193014 — leukemia, leukemia, myeloid, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive		Cancers (Basel)20260
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.
PMID 42179186 — neoplasms, therapeutics, spleen, primary myelofibrosis		Oncologist20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 8
Phase 2 5
N/A 4
Phase 1/Phase 2 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 9
Recruiting 4
Terminated 3
Active not recruiting 2
Unknown 2
Not yet recruiting 1

By type:

Interventional 19
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 1
multicentricup10 16

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma
2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics		Phase 3Active not recruiting2021
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
2023-504724-25-00 — thrombocythemia, essential, polycythemia vera, safety, thrombocytosis, polycythemia, random allocation, primary myelofibrosis		Phase 3Recruiting2024
Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
NCT06119269 — pharmaceutical preparations, genes, abl, drug monitoring, leukemia, leukemia, myeloid, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive, plasma		N/ARecruiting2023
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
NCT06516406 — thrombocythemia, essential, polycythemia vera, safety, thrombocytosis, neoplasms, neoplasm metastasis, polycythemia, primary myelofibrosis		N/ARecruiting2022
Lifestyles Implemented Survivorship Care Plan In Lymphoma Survivors
NCT05934084 — exercise, cells, quality of life, life style, hodgkin disease, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, motor activity, survivorship, b-lymphocytes		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS